Inverse agonism at G protein-coupled receptors: (Patho)physiological relevance and implications for drug discovery

British Journal of Pharmacology

Volumn 130, Issue 1, 2000, Pages 1-12

  De Ligt, Rianne A F ^a   Kourounakis, Angeliki P ^a   IJzerman, Ad P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

GPCR; Implications drug discovery; Inverse agonism; Negative efficacy; Neutral antagonist; Review

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 5 CARBAMOYLTRYPTAMINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; ATROPINE; BURIMAMIDE; CHLORPROMAZINE; CIMETIDINE; DEXMEDETOMIDINE; FAMOTIDINE; FLUPHENAZINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; HALOPERIDOL; MEDETOMIDINE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NAFADOTRIDE; PINDOLOL; PROPRANOLOL DERIVATIVE; RANITIDINE; RIMONABANT; SCOPOLAMINE; YOHIMBINE;

ANIMAL CELL; CHONDRODYSPLASIA; DRUG DEVELOPMENT; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HYPERTHYROIDISM; HYPOPARATHYROIDISM; NONHUMAN; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW;

EID: 0034016295     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703311     Document Type: Review

References (84)

1. 2 receptor. J. Neurochem., 71, 799-807.
2. APPELMANS, N., CARROLL, J.A., RANCE, M.J., SIMON, E.J. & TRAYNOR, J.R. (1986). Sodium ions increase the binding of the antagonist peptide ICI 174864 to the delta opiate receptor. Neuropeptides, 7, 139-143.
3. 2C receptor systems. Mol. Pharmacol., 55, 863-872.
4. BERRIE, C.P., BIRDSALL, N.J., BURGEN, A.S. & HULME, E.C. (1979). Guanine nucleotides modulate muscarinic receptor binding in the heart. Biochem. Biophys. Res. Commun., 87, 1000-1005.
5. BOND, R.A., LEFF, P., JOHNSON, T.D., MILANO, C.A., ROCKMAN, H.A., MCMINN, T.R., APPARSUNDARAM, S., HYEK, M.F., KENAKIN, T.P., ALLEN, L.F. & LEFKOWITZ, R.J. (1995). Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta(2)-adrenoceptor. Nature, 374, 272-276.
6. 2: implication for intracellular signalization cross-regulation. Mol. Pharmacol., 55, 473-480.
7. BOUABOULA, M., PERRACHON, S., MILLIGAN, L., CANAT, X., RINALDI-CARMONA, M., PORTIER, M., BARTH, F., CALANDRA, B., PECCEU, F., LUPKER, J., MAFFRAND, J.P., LE FUR, G. & CASELLAS, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem., 272, 22330-22339.
8. BRAESTRUP, C., SCHMIECHEN, R., NEEF, G., NIELSEN, M. & PETERSEN, E.N. (1982). Interaction of convulsive ligands with benzodiazepine receptors. Science, 216, 1241-1243.
9. BURGISSER, E., DE LEAN, A. & LEFKOWITZ, R.J. (1982). Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc. Natl. Acad. Sci. U.S.A. 79, 1732-1736.
10. BURSTEIN, E.S., SPALDING, T.A. & BRANN, M.R. (1997). Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol. Pharmacol., 51, 312-319.
11. 1-receptor binding sites in guinea pig brain membranes: regulation of agonist interactions by guanine nucleotides and cations. J. Neurochem., 34, 916-922.
12. CHIALE, P.A., ROSENBAUM, M.B., ELIZARI, M.V., HJALMARSON, A., MAGNUSSON, Y., WALLUKAT, G. & HOEBEKE, J. (1995). High prevalence of antibodies against beta 1-and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities. J. Am. Coll. Cardiol., 26, 864-869.
13. CHIDIAC, P., HEBERT, T.E., VALIQUETTE, M., DENNIS, M. & BOUVIER, M. (1994). Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol., 45, 490-499.
14. COHEN, D.P., THAW, C.N., VARMA, A., GERSHENGORN, M.C. & NUSSENZVEIG, D.R. (1997). Human calcitonin receptors exhibit agonist-independent (constitutive) signaling activity. Endocrinology. 138, 1400-1405.
15. COSTA, T. & HERZ, A. (1989). Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A., 86, 7321-7325.
16. COSTA, T., LANG, J., GLESS, C. & HERZ, A. (1990). Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol. Pharmacol., 37, 383-394.
17. COTECCHIA, S., EXUM, S., CARON, M.G. & LEFKOWITZ, R.J. (1990). Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl. Acad. Sci. U.S.A., 87, 2896 2900.
18. CRUZ, S.L., VILLARREAL, J.E. & VOLKOW, N.D. (1996). Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci., 58, L381-L389.
19. DE LEAN, A., STADEL, J.M. & LEFKOWITZ, R.J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem., 255, 7108-7117.
20. DEL CASTILLO, J. & KATZ, B. (1957). Interaction at end-plate receptors between different choline derivatives. Proc. Roy. Soc. Lond. B., 146, 369-381.
21. EHLERT, F.J. (1985). The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol., 28, 410-421.
22. ELIES, R., FERRARI, I., WALLUKAT, G., LEBESGUE, D., CHIALE, P., ELIZARI, M., ROSENBAUM, M., HOEBEKE, J. & LEVIN, M.J. (1996). Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J. Immunol., 157, 4203-4211.
23. ENG, H., MAGNUSSON, Y., MATELL, G., LEFVERT, A.K., SAPONJA, R. & HOEBEKE, J. (1992). Beta 2-adrenergic receptor antibodies in myasthenia gravis. J. Autoimmun., 5, 213-227.
24. EUROPE-FINNER, G.N., PHANEUF, S., TOLKOVSKY, A.M., WATSON, S.P., LOPEZ BERNAL A. (1994). Down-regulation of G alpha s in human myometrium in term and preterm labor: a mechanism for parturition. J. Clin. Endocrinol. Metab., 79, 1835-1839.
25. FU, M.L., HOEBEKE, J., MATSUI, S., MATOBA, M., MAGNUSSON, Y., HEDNER, T., HERLITZ, H. & HJALMARSON, A. (1994). Autoantibodies against cardiac G-protein-coupled receptors define different populations with cardiomyopathies but not with hypertension. Clin. Immunol. Immunopathol., 72, 15-20.
26. GARDELLA, T.J., LUCK, M.D., JENSEN, G.S., SCHIPANI, E., POTTS, J.T., JR. & JËPPNER, H. (1996). Inverse agonism of aminoterminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology. 137, 3936 3941.
27. GERAS-RAAKA, E., VARMA, A., HO, H., CLARK LEWIS, I. & GERSHENGORN, M.C. (1998). Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J. Exp. Med. 188, 405-408.
28. + regulation of formyl peptide receptor-mediated signal transduction in HL 60 cells. Evidence that the cation prevents activation of the G-protein by unoccupied receptors. Eur. J. Pharmacol., 172, 481-492.
29. GÖTZE, K. & JAKOBS, K.H. (1994). Unoccupied beta-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. Eur. J. Pharmacol., 268, 151-158.
30. GREEN, R.D. (1984). Reciprocal modulation of agonist and antagonist binding to inhibitory adenosinc receptors by 5′-guanylylimidodiphosphate and monovalent cations. J. Neurosci., 4, 2472-2476.
31. 3 receptor. J. Neural. Transm., 103, 1163-1175.
32. GUILLET, J.G., LENGAGNE, R., MAGNUSSON, Y., TATE, K., STROSBERG, A.D. & HOEBEKE, J. (1992). Induction of a pharmacologically active clonotypic B cell response directed to an immunogenic region of the human beta 2-adrencrgic receptor. Clin. Exp. Immunol., 89, 461-467.
33. 2+ and K currents in frog and rat cardiac cells. J. Physiol. Lond., 461, 743 765.
34. HILF, G. & JAKOBS, K.H. (1992). Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur. J. Pharmacol., 225, 245-252.
35. HORSTMAN, D.A., BRANDON, S., WILSON, A.L., GUYER, C.A., CRAGOE JR., E.J. & LIMBIRD, L.E. (1990). An aspartate conserved among G-protein receptors confers allosleric regulation of alpha 2-adrencrgic receptors by sodium. J. Biol. Chem., 265, 21590-21595.
36. HUGHES, R.J., MAHAN, L.C. & INSEL, P.A. (1988). Certain beta-blockers can decrease beta-adrenergic receptor number: II. Down-regulation of receptor number by alprenolol and propranolol in cultured lymphoma and muscle cells. Circ. Res., 63, 279 285.
37. UZERMAN, A.P., VAN DER WENDEN, E.M., ROELEN, H.C.P.F., MATHÔT, R.A.A. & VON FRIJTAG DRABBE KÜNZEL, J.K. (1996). Partial agonists for adenosine receptors. In: Perspectives in Receptor Research. ed. Giardinà, D., Piergentili, A. & Pigini, M. pp. 181-192. Amsterdam: Elsevier.
38. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett., 377, 275-279.
39. JANSSON, C.C., KUKKONEN, J.P., NÄSMAN, J., HUIFANG, G., WURSTER, S., VIRTANEN, R., SAVOLA, J.M., COCKCROFT, V. & ÄKERMAN, K.E. (1998). Protean agonism at alpha2A-adrenoceptors. Mol. Pharmacol., 53, 963-968.
40. KINSLER, V.A., THORNTON, S., ASHFORD, M.L., MELIN, P. & SMITH, S.K. (1996). The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Br. J. Obstet. Gynaecol., 103, 373-375.
41. 1 receptor. Life Sci., 62, L109-L113.
42. LEEB-LUNDBERG, L.M.F., MATHIS, S.A. & HERZIG, M.C.S. (1994). Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J. Biol. Chem., 269, 25970-25973.
43. LEFF, P. (1995). The two-state model of receptor activation. Trends Pharmacol. Sci., 16, 89-97.
44. LEURS, R., SMIT, M.J., ALEWIJNSE, A.E. & TIMMERMAN, H. (1998). Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem. Sci., 23, 418-422.
45. 1 adenosine receptors in brain membranes. Analysis of guanine nucleotide and temperature effects on radioligand binding. Mol. Pharmacol., 26, 1-9.
46. LU, D., WILLARD, D., PATEL, I.R., KADWELL, S., OVERTON, L., KOST, T., LUTHER, M., CHEN, W., WOYCHIK, R.P., WILKISON, W.O. et al. (1994). Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature, 371, 799-802.
47. MACEWAN, D.J. & MILLIGAN, G. (1996). Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol. Pharmacol., 50, 1479-1486.
48. 2 receptors. Br. J. Pharmacol., 124, 619-622.
49. MAGNUSSON, Y., MARULLO, S., HOYER, S., WAAGSTEIN, F., ANDERSSON, B., VAHLNE, A., GUILLET, J.G., STROSBERG, A.D., HJALMARSON, A. & HOEBEKE, J. (1990). Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest., 86, 1658-1663.
50. MEWES, T., DUTZ, S., RAVENS, U. & JAKOBS, K.H. (1993). Activation of calcium currents in cardiac myocytes by empty beta-adrenoceptors. Circulation, 88, 2916-2922.
51. MIJARES, A., LEBESGUE, D., ARGIBAY, J. & HOEBEKE, J. (1996). Anti-peptide antibodies sensitive to the 'active' state of the beta2-adrenergic receptor. FEBS Lett., 399, 188-191.
52. MILLIGAN, G., MACEWAN, D.J., MERCOURIS, M. & MULLANEY, I. (1997). Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors. Receptors Channels, 5, 209-213.
53. MOLINOFF, P.B. & AARONS, R.D. (1983). Effects of drugs on beta-adrenergic receptors on human lymphocytes. J. Cardiovasc. Pharmacol., 5, S63-S67.
54. MONOD, J., WYMAN J. & CHANGEAUX J-P. (1965). On the nature of allosteric transitions: a plausible model. J. Biol. Chem., 12, 88-118.
55. MORRIS, B.J., MILLAN, M.J. & HERZ, A. (1988). Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography. J. Pharmacol. Exp. Ther., 247, 729-736.
56. NAGARAJA, S., IYER, S., LIU, X., EICHBERG, J. & BOND, R.A. (1999). Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with beta2-adrenoceptor activation. Br. J. Pharmacol., 127, 1099-1104.
57. 125I]epidepride, a high-affinity substituted benzamide ligand. J. Pharmacol. Exp. Ther., 252, 1108-1116.
58. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br. J. Pharmacol., 120, 737-739.
59. NISWENDER, C.M., COPELAND, S.C., HERRICK-DAVIS, K., EMESON, R.B., SANDERS-BUSH, E. (1999). RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem., 274, 9472-9478.
60. NOGUERA, M.A., IVORRA, M.D. & D'OCON, P. (1996). Functional evidence of inverse agonism in vascular smooth muscle. Br. J. Pharmacol., 119, 158-164.
61. + exchange. J. Biol. Chem., 262, 12387-12392.
62. 1 cannabinoid receptor activity. Mol. Pharmacol., 54, 1064-1072.
63. PERT, C.B. & SNYDER S.H. (1974). Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol. Pharmacol., 10, 868-870.
64. POZVEK, G., HILTON, J.M., QUIZA, M., HOUSSAMI, S. & SEXTON, P.M. (1997). Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Mol. Pharmacol., 51, 658-665.
65. 1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein. J. Pharmacol. Exp. Ther., 246, 1194-1200.
66. RICHARDSON, J.D., AANONSEN, L. & HARGREAVES, K.M. (1997). SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol., 319, R3-R4.
67. 1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J. Pharmacol. Exp. Ther., 287, 1038-1047.
68. ROSENKILDE, M.M., KLEDAL, T.N., BRÄUNER-OSBORNE, H. & SCHWARTZ, T.W. (1999). Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J. Biol. Chem., 274, 956-961.
69. SAMAMA, P., BOND, R.A., ROCKMAN, H.A., MILANO, C.A. & LEFKOWITZ, R.J. (1997). Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 94, 137-141.
70. SAMAMA, P., COTECCHIA, S., COSTA, T. & LEFKOWITZ, R.J. (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem., 268, 4625-4636.
71. SCHIPANI, E., LANGMAN, C.B., PARFITT, A.M., JENSEN, G.S., KIKUCHI, S., KOOH, S.W., COLE, W.G. & JÜPPNER, H. (1996). Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia [see comments]. N. Engl. J. Med., 335, 708-714.
72. SERRE, V., DOLCI, W., SCHAERER, E., SCROCCHI, L., DRUCKER, D., EFRAT, S. & THORENS, B. (1998). Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology, 139, 4448-4454.
73. SIEGRIST, W., DROZDZ, R., COTTI, R., WILLARD, D.H., WILKISON, W.O. & EBERLE, A.N. (1997). Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. J. Recept. Signal Transduct. Res., 17, 75-98.
74. 2 receptors. Proc. Natl. Acad. Sci. U.S.A., 93, 6802-6807.
75. SPIEGEL, A.M. (1996). Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol., 58, 143-170.
76. STADEL, J.M., WILSON, S. & BERGSMA, D.J. (1997). Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. Trends Pharmacol. Sci., 18, 430-437.
77. 1 adenosine receptor-G protein coupling in bovine brain membranes: effects of guanine nucleotides, salt, and solubilization. J. Neurochem., 51, 1592-1598.
78. 1-adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 340, 87-92.
79. SZEKERES, P.G. & TRAYNOR, J.R. (1997). Delta opioid modulation of the binding of guanosine-5′-O-(3-[S-35]thio)triphosphate to NG108-15 cell membranes: Characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther., 283, 1276-1284.
80. TIAN, W.-N., DUZIC, E., LANIER, S.M. & DETH, R.C. (1994). Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol. Pharmacol., 45, 524-531.
81. 1B receptor subtype. J. Biol. Chem., 269, 27925-27931.
82. TSAI, B.S. & LEFKOWITZ, R.J. (1978). Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol. Pharmacol., 14, 540-548.
83. WENZEL-SEIFERT, K., HURT, C.M. & SEIFERT, R. (1998). High constitutive activity of the human formyl peptide receptor. J. Biol. Chem., 273, 24181-24289.
84. 2-dopamine receptor of the anterior pituitary gland. Mol. Pharmacol., 26, 214-227.